Applied Genetic Technologies (AGTC) Misses Q4 EPS by 24c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Applied Genetic Technologies Corp. (AGTC) PT Lowered to $12 at Stifel
September 13, 2017 4:27 PM EDTStifel lowered its price target on Applied Genetic Technologies Corp. (NASDAQ: AGTC) to $12.00 (from $15.00) while maintaining a Buy rating following the company's 4Q. Net loss of $3.2M, or $(0.18)/share, was wider than the Consensus estimate of $0.08. Lower-than-anticipated collaborative revenue drove the majority of the... More
UPDATE: Applied Genetic Technologies Corp. (AGTC) PT Lowered to $7 at BMO Capital; Lower Probability of XLRS Success
September 13, 2017 12:05 PM EDT(Updated - September 13, 2017 12:07 PM EDT)
(correction: price target lowered not raised)
BMO Capital lowered its price target on Applied Genetic Technologies Corp. (NASDAQ: AGTC) to $7 (from $14) while maintaining a Outperform rating.
Analyst Matthew Luchini cited a lower probability of success for the lead XLRS program to 40% from 70%.
... MoreApplied Genetic Technologies Corp. (AGTC) PT Lowered to $8 at H.C. Wainwright, Keeps 'Buy'
September 13, 2017 9:39 AM EDTH.C. Wainwright lowered its price target on Applied Genetic Technologies Corp. (NASDAQ: AGTC) to $8.00 (from $16.00) while maintaining a Buy rating.
Analyst Joseph Pantginis said while programs are chugging along, timelines were pushed out again.
... More